Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604600 | 0.81 | CYP1A2 (0.58) | SMN1; SMN2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL6075048 | 0.81 | CYP1A2 (0.58) | SMN1; SMN2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL18151630 | 0.79 | HDAC3 (0.58) | SMN1; SMN2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL8151739 | 0.79 | NAAA (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL8151740 | 0.79 | NAAA (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL6551872 | 0.77 | RAB9A (0.58) | SMN1; SMN2ALDH1A1LMNAGAANPC1 | |
| SCHEMBL17188462 | 0.77 | RAB9A (0.58) | SMN1; SMN2ALDH1A1LMNAGAANPC1 | |
| SCHEMBL6551341 | 0.76 | NPC1 (0.56) | SMN1; SMN2ALDH1A1LMNAGAANPC1 | |
| SCHEMBL4611015 | 0.74 | NPC1 (0.54) | ALDH1A1LMNAGAANPC1RAB9A | |
| SCHEMBL1416655 | 0.74 | RAB9A (0.49) | L3MBTL1ALDH1A1LMNAGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346845-B2 | Anionic conjugates of glycosylated bacterial metabolite | GLYCAN BIOSCIENCES LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | Glycosynnovations Pty Ltd (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8791245-B2 | Anionic conjugates of glycosylated bacterial metabolite | Glycan Bioscience LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-04 | — | — | US | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | CUMBERLAND PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| US-6518242-B1 | Derivatives of glycopeptide antibacterial agents | THERAVANCE, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6288055-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS; PYRIDINE DERIVATIVES LINKED BY LIGAND | ADVANCED MEDICINE, INC. | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | SMN1; SMN2 3893/4885L3MBTL1 1541/4885ALDH1A1 1240/4885 |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | ENGASE, GALE, MGAM | SMN1; SMN2 4811/4885L3MBTL1 1949/4885ALDH1A1 2635/4885 |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | GNE, CD44, FUT5 | SMN1; SMN2 3893/4885L3MBTL1 1541/4885ALDH1A1 1240/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | SMN1; SMN2 4046/4885L3MBTL1 3638/4885ALDH1A1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.